Israël classé au 4ème rang mondial pour ses publications d’articles scientifiques selon les renseignements rassemblés par le Haut Conseil de l’Education. Les données, datant de 2005, placent Israël derrière la Suisse, la Suède et le Danemark en termes de nombre de publications scientifiques par million d’habitants. Le rapport a été communiqué lors d’une conférence à l’Université Bar Ilan le 16 novembre dernier. En 2005, les scientifiques israéliens ont publié 6309 articles dans des journaux scientifiques étrangers devant la Finlande, les Pays-Bas et le Canada. Les Etats-Unis occupent la 12ème place et l’Allemagne la 15ème. 0.89 % des articles scientifiques publiés en 2005 ont été écrits par des scientifiques israéliens. En 1997, 1.83% des articles mondiaux l’étaient par des Israéliens.
Ongoing research at an Israeli university may lead to vaccines that can teach our immune systems to better fight Alzheimer's disease. An Israeli researcher who is working on a vaccine for Alzheimer's has discovered that it is possible to test and measure specific immune responses in mice carrying human genes and to anticipate the immune response in Alzheimer's patients.
Photo by Chen Leopold/Flash90: Solel Solar's parabolic solar collector in Beit Shemesh. The company manufactures solar collectors for solar fields all over the world.
Yissum, société de transfert des technologies de l’Université Hébraïque de Jérusalem, a annoncé avoir signé un accord de collaboration et de recherche multi-projets avec le groupe pharmaceutique suisse Roche. Dans le cadre de cet accord, Roche a sélectionné six projets de recherche prometteurs, initiés par les chercheurs de l’Université Hébraïque, dans les domaines des cellules souches, des biomarqueurs et des nouvelles molécules pour le traitement des maladies métaboliques. La durée prévue de chaque projet de recherche est entre un et trois ans. Après la réussite des différents travaux, Roche aura la licence exclusive pour commercialiser les résultats.
Grants totaling £365,000 were awarded to 15 projects under the Britain-Israel Research and Academic Exchange Partnership, it was announced in London on Saturday. The partnership is managed by the British Council.
Israel could become a leader in the $3 billion chronic wound industry with a new device that heals wounds faster and more cheaply than alternatives. Millions of Americans, particularly the elderly and diabetics, are afflicted with chronic wounds, which are complicated to treat and can lead to lengthy hospital stays. With life expectancy and the numbers of those suffering from diabetes and obesity increasing worldwide, the global chronic wound industry currently totals around $3 billion. Israeli company EnzySurge hopes to change the way chronic wounds are treated, with its DermaStream product line. The device is relatively low-cost, has the appearance of a bandage and is disposable, unlike the unwieldy equipment in use today.
The journalistic ethos of the Axel Springer publishing house - Europe's largest media conglomerate - is governed by a set of principles spelled out in the employment contract of each journalist, one of which advocates "the support of the State of Israel and its existence and reconciliation between Germans and Jews."
Self-cleaning skyscraper and car windows and solar panels that repel water and dirt, as well as high-power rechargeable batteries for electric vehicles could be some of the major applications of a Tel Aviv University nanotechnology discovery announced on Sunday evening.
Prix Nobel de chimie 2009, Ada Yonath, 70 ans, la première Israélienne distinguée par l'Académie suédoise, s'est inspirée de Marie Curie pour étudier, dans des conditions modestes, et poursuivre ses recherches scientifiques au niveau le plus élevé. "Rien dans mon enfance ne laissait penser que j'atteindrais ce niveau, même si mes parents et ma famille ont toujours cru à la possibilité d'une reconnaissance", a déclaré Ada Yonath à la radio israélienne, en pleurant, après l'annonce de son prix.
Israeli scientist Prof. Ada Yonath has won this year's Nobel Prize in chemistry for her groundbreaking work in the field of ribosomes. When Israeli scientist Professor Ada Yonath was growing up, her role model was the Polish-French scientist Marie Curie, the pioneer in the field of radioactivity. During her lifetime Marie Curie was awarded two Nobel prizes in different scientific fields. Now, fittingly, Yonath has been awarded a Nobel prize of her own. Yonath, who is 70, was awarded this year's Nobel Prize in chemistry for her groundbreaking work in understanding how cells build proteins. She is only the fourth woman to win the Nobel chemistry prize, and the first since 1964, when British woman Dorothy Crowfoot Hodgkin received the prize.
After demonstrating in rats that they can use human embryonic stem cells (hESCs) to halt the decline in and rescue the retinal function of lab animals that model age-related macular degeneration (AMD), Hadassah University Medical Center researchers believe they can start clinical trials on people in two years. AMD - the principal cause of vision loss in residents of the Western world over the age of 50 - occurs when pigmented cells of the macula (center of the retina at the back of the eye) break down and die. The painless disease gradually destroys sharp, central vision, which is needed to see objects clearly and for common daily tasks such as reading and driving. Some 30 million people around the globe and many tens of thousands of Israelis suffer from AMD, and a growing number are unable to function normally.
The tiniest medical camera in the world, invented by an Israeli company, measures 0.05 inches, is cheap to produce and should eliminate the need for many invasive, costly and risky procedures. Seeing is believing when it comes to many medical diagnoses, and that often necessitates invasive surgical procedures, X-rays and radioactive dyes. But what if you could just use a camera?
Haifa scientists have adapted an innovative Japanese gene-implantation technique and succeeded in "turning back the clock" for human skin cells, reprogramming them into artificial embryonic stem cells and then switching them into heart cells in the lab. Although implementing this clinically to repair damaged human hearts is at least a decade or two away, the Israeli accomplishment can already be utilized for in-depth study of genetic diseases and the development of personalized drugs for inherited disorders, such as those involving irregular heartbeat.
Tombé à la quatrième place des exportateurs mondiaux de matériel militaire, la France perd du terrain et est désormais talonnée par Israël.
Israeli researchers have developed a protein-based injection that can spark the regrowth of tiny blood vessels, offering hope of an alternative treatment to the hundreds of thousands of people undergoing open-heart surgery every year.